• If you are wondering whether Encompass Health is attractively priced or simply appears that way on the surface, this article walks through what the current share price might be implying about the stock's value.
• The stock last closed at US$98.03, with the share price down 4.2% over the past week and 6.4% over the past month, while still sitting above levels from three and five years ago based on returns of 52.6% and 62.4% across those periods.
• Over the past year, Encompass Health has seen its share price fall 17.6%, which has sharpened the focus on what investors are currently paying for its future prospects. Broader sector interest in healthcare services and capital allocation decisions across the industry have also kept valuation in the spotlight for stocks like Encompass Health.
• Right now, the company scores 5 out of 6 on Simply Wall St's valuation checks. You can see the full breakdown of that score here. This sets up a closer look at traditional valuation tools such as P/E and DCF models, followed by a more holistic way to think about what Encompass Health might be worth.

Approach 1: Encompass Health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what Encompass Health might be worth by projecting future cash flows and discounting them back to today, so you can compare that value with the current share price.

For Encompass Health, the model used is a 2 Stage Free Cash Flow to Equity approach. The company’s last twelve months Free Cash Flow is about $457.3 million. Analysts provide explicit forecasts for the next few years, and Simply Wall St extends those projections further. By 2028, projected Free Cash Flow is $576.0 million, with additional estimates running out to 2035, all expressed in dollars and adjusted using discount rates to reflect today’s value.

Bringing all those discounted cash flows together gives an estimated intrinsic value of $166.57 per share. Compared with the recent share price of $98.03, this implies the stock trades at about a 41.1% discount to the DCF estimate, which suggests that Encompass Health may be undervalued according to this model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Encompass Health is undervalued by 41.1%. Track this in your watchlist or portfolio, or discover 45 more high quality undervalued stocks.

Approach 2: Encompass Health Price vs Earnings

For a profitable company like Encompass Health, the P/E ratio is a useful way to think about what you are paying for each dollar of earnings. A higher P/E often reflects higher growth expectations or lower perceived risk, while a lower P/E can point to more muted growth expectations or higher risk.

Encompass Health currently trades on a P/E of 16.42x. That sits below the broader Healthcare industry average P/E of 23.40x and slightly above the peer group average of 15.65x. On the surface, that suggests the stock is priced below the wider industry, but not out of line with closer peers.

Simply Wall St’s Fair Ratio for Encompass Health is 21.80x. This is the P/E level that its model suggests might be appropriate after considering factors such as earnings growth, industry, profit margins, market cap and company specific risks. This Fair Ratio can be more informative than a simple comparison with peers or the industry because it adjusts for the company’s own characteristics rather than assuming all healthcare stocks deserve similar multiples. With the current P/E of 16.42x sitting below the Fair Ratio of 21.80x, the stock appears undervalued on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Encompass Health Narrative

Earlier we mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you turn your view of Encompass Health into a clear story that links its business, a financial forecast and a fair value. The Narrative then compares that fair value to the current price to help you decide if the stock looks expensive or cheap relative to your assumptions. Each Narrative lives on the Community page, updates automatically when fresh news or earnings arrive, and can reflect different perspectives, such as a more optimistic view that aligns with an upper fair value near US$152.00 or a more cautious view closer to US$99.17. All of this is expressed through your own expectations for future revenue, earnings and margins.

Do you think there's more to the story for Encompass Health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.